Unknown

Dataset Information

0

COVID-19 in patients with hematological malignancies: Considering the role of tyrosine kinase inhibitors.

ABSTRACT:

SUBMITTER: Morales-Ortega A 

PROVIDER: S-EPMC8250378 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies.
| S-EPMC5920436 | biostudies-literature
Unknown COVID-19 in vaccinated adult patients with hematological malignancies. Preliminary results from EPICOVIDEHA
| S-EPMC8577877 | biostudies-literature
Unknown Checkpoint inhibitors in hematological malignancies.
| S-EPMC5422942 | biostudies-literature
Unknown The promise of Janus kinase inhibitors in the treatment of hematological malignancies.
| S-EPMC5854188 | biostudies-other
Unknown The Possible Role of Bruton Tyrosine Kinase Inhibitors in the Treatment of COVID-19: A Review.
| S-EPMC8673731 | biostudies-literature
Unknown COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
| S-EPMC8515781 | biostudies-literature
Unknown AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma.
| S-EPMC6896070 | biostudies-literature
Unknown Role of CD47 in Hematological Malignancies.
| S-EPMC7364564 | biostudies-literature
Unknown Role of Bruton's tyrosine kinase in B cells and malignancies.
| S-EPMC5817726 | biostudies-literature
Unknown Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review.
| S-EPMC8318668 | biostudies-literature